Wir sind mit live! Mehr erfahren

Baxter International

BAX

Börsenwert 13,1 Mrd. $

25,28 USD

-0,48

1,86 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

25,30

+0,02

0,08 %

1 Tag

-1,86 %

5 Tage

3,44 %

1 Monat

7,44 %

3 Monate

8,27 %

6 Monate

39,36 %

Seit Jahresbeginn

29,64 %

1 Jahr

10,06 %

5 Jahre

-67,66 %

10 Jahre

-46,63 %

Profil: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Mitarbeiter: 37.500

Gesundheitswesen Medizinische Geräte und Verbrauchsmaterialien

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 52 %

Neutral 40 %

Negativ 8 %

Baxter International: The Vantive Transition Complicates Margin Recovery

Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.

Baxter International: The Vantive Transition Complicates Margin Recovery

Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.

Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors

Zacks Investment Research

Are Investors Undervaluing Baxter International (BAX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Baxter International (BAX) Right Now?

Zacks Investment Research

Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?

Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?

Baxter Releases Inaugural Connected Hospital Report

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes. Based on a survey of 150 information technology (IT) and nursing leaders, the report examines how hospitals are progressing along a “connected hospital” journey by identifying four distin.

Baxter Releases Inaugural Connected Hospital Report

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Baxter Appoints John Rogers Chief Financial Officer

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. “John is a proven global finance executive with extensive operational expertise and a successful track record leading complex transformation initiatives,” said Hider. “He is an ideal fit for.

Baxter Appoints John Rogers Chief Financial Officer

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt